The EHBP1 Knockout Raji Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human Raji B lymphocyte line, designed to provide a loss-of-function model for studying the endocytic adaptor protein EHBP1. This engineered cell pool carries a heterogeneous array of modifications at the EHBP1 locus, enabling functional interrogation of EHBP1-dependent processes without the constraints of clonal selection. The polyclonal format captures the genetic diversity of CRISPR-mediated disruptions, offering a robust system for bulk cellular assays and minimizing clonal artifacts that can arise in single-cell-derived models.
The parental Raji cell line is a well-established suspension culture of human B lymphocytes originating from a patient with Burkitt lymphoma, characterized by its Epstein?CBarr virus (EBV)-positive status and rapid proliferation. These cells retain key hallmarks of B cell biology, including the capacity for antibody production, antigen presentation, and active receptor-mediated endocytosis. Their lymphoid origin and intact immune signaling pathways make Raji cells a classic model for hematological malignancies, immunoglobulin trafficking, and B cell receptor (BCR) internalization studies.
EHBP1 (EH domain-binding protein 1) functions as a molecular scaffold that integrates endocytic trafficking with actin cytoskeleton dynamics. It couples EH domain-containing proteins, such as the prototypical endocytic adaptor Eps15, to the actin nucleation machinery via N-WASP and the Arp2/3 complex, while simultaneously interacting with Rab10 and sorting nexins to coordinate endosomal cargo sorting and membrane recycling. Through these interactions, EHBP1 orchestrates the spatial and temporal regulation of receptor internalization and recycling downstream of receptor tyrosine kinases and Rab GTPase signaling modules. The disrupted gene product therefore sits at a critical node linking vesicle trafficking to cytoskeletal reorganization, with downstream consequences for actin polymerization, endosomal maturation, and membrane dynamics.
In the Raji B cell context, EHBP1 plays a particularly consequential role by controlling the endocytic fate of surface receptors, including the BCR, which is essential for antigen uptake, processing, and presentation. Disruption of EHBP1 in these cells is expected to impair receptor recycling and alter the balance between endosomal sorting and degradation, potentially affecting downstream immune signaling and tumor cell phenotypes. Given the association of EHBP1 with rare intellectual disability and its emerging relevance in cancer biology, this Raji knockout model provides a unique lymphoid platform to dissect EHBP1 contributions to both normal B cell physiology and malignant transformation.
Researchers can employ this polyclonal population in a broad array of experimental applications, including endocytosis uptake assays to quantify internalization kinetics, flow cytometry-based receptor recycling assays to monitor BCR trafficking, and immunofluorescence microscopy to visualize actin cytoskeleton rearrangements and endosomal distribution. Co-immunoprecipitation and Western blotting enable verification of disrupted EHBP1 interactions with partners such as Eps15, Rab10, and N-WASP, while actin polymerization assays probe downstream cytoskeletal effects. These applications position the EHBP1 Knockout Raji Polyclonal Cells as a versatile tool for mechanistic studies in hematological cell biology, drug targeting of membrane trafficking, and the exploration of EHBP1 as a therapeutic vulnerability. For further product details and technical support, please contact Ascent Research.
